E2F1 and breast cancer: Among these transcription factors, STAT1, MAPK1, FOXA1, TFAP2C, E2F1 are associated with resistance or insensitivity to several anticancer therapies including tyrosine kinase inhibitors such as lapatinib in BC cells [44–51].